Next report date
Report period
Q1 2024
EPS estimate
−0.35USD
Revenue estimate
—
−51.06 MUSD
27.49 M
Om Viracta Therapeutics, Inc.
Sektor
Bransch
VD
Mark A. Rothera
Webbplats
Huvudkvarter
Cardiff
Employees (FY)
40
Grundat
1998
FIGI
BBG000BFG2V7
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
